Vertex Announces Plan to Expand Cell and Gene Therapy Footprint


Vertex Pharmaceuticals Incorporated has announced plans to set up another 344,000 sq ft facility in the Seaport to support the company’s continued rapid growth of its cell and genetic therapies programs.

Article Summary

The completion of the new site at Seaport is expected in 2025 following which Vertex will occupy 1.9 million square feet of real estate in the Seaport across five sites, making it the largest biotech in Boston in terms of square footage. 

Jeffrey Leiden, M.D., Ph.D., Executive Chairman at Vertex stated that this expansion is a sign of their deep commitment to Boston and the larger Massachusetts innovation ecosystem. These buildings represent a further significant investment in their unique R&D strategy, to transform the lives of people with serious diseases, like sickle cell disease and type 1 diabetes, using cutting-edge genetic and cell-based therapies.

In addition to this expansion, Vertex and the Vertex Foundation have also announced a $50 million commitment to health equity focused on clinical trial diversity, access to quality care, and education of the local health care workforce.

About Vertex

Founded in 1989 in Cambridge, Mass., Vertex is a global biotech company with multiple approved medicines to treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. The company’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. The company has research and development sites and commercial offices in North America, Europe, Australia and Latin America.

 (Source: Vertex, 17th May 2022)


Leave A Comment

Leave a Reply

Your email address will not be published.